Searle & CO. Takes Position in Ascendis Pharma A/S (NASDAQ:ASND)

Searle & CO. bought a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,500 shares of the biotechnology company’s stock, valued at approximately $205,000.

Several other hedge funds have also recently added to or reduced their stakes in ASND. GAMMA Investing LLC purchased a new position in Ascendis Pharma A/S in the fourth quarter worth approximately $25,000. Private Ocean LLC acquired a new position in shares of Ascendis Pharma A/S during the first quarter worth $36,000. Quadrant Capital Group LLC increased its holdings in Ascendis Pharma A/S by 90.4% in the fourth quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 151 shares during the last quarter. EverSource Wealth Advisors LLC increased its holdings in Ascendis Pharma A/S by 37.6% in the fourth quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company’s stock valued at $42,000 after buying an additional 91 shares during the last quarter. Finally, Barometer Capital Management Inc. purchased a new stake in Ascendis Pharma A/S during the 4th quarter worth about $126,000.

Wall Street Analysts Forecast Growth

ASND has been the subject of several analyst reports. StockNews.com cut Ascendis Pharma A/S from a “hold” rating to a “sell” rating in a research report on Tuesday, August 13th. JPMorgan Chase & Co. increased their price target on shares of Ascendis Pharma A/S from $170.00 to $174.00 and gave the company an “overweight” rating in a research note on Wednesday, August 21st. Cantor Fitzgerald reissued an “overweight” rating and set a $173.00 price objective on shares of Ascendis Pharma A/S in a report on Wednesday, May 15th. Stifel Nicolaus began coverage on shares of Ascendis Pharma A/S in a report on Friday, May 31st. They issued a “buy” rating and a $200.00 target price for the company. Finally, Morgan Stanley increased their target price on shares of Ascendis Pharma A/S from $116.00 to $140.00 and gave the company an “equal weight” rating in a research report on Thursday, May 16th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Ascendis Pharma A/S presently has a consensus rating of “Moderate Buy” and a consensus price target of $185.00.

Ascendis Pharma A/S Trading Up 0.4 %

Shares of NASDAQ ASND traded up $0.51 during midday trading on Friday, reaching $138.45. 222,674 shares of the company were exchanged, compared to its average volume of 371,471. The stock has a market cap of $8.06 billion, a P/E ratio of -14.41 and a beta of 0.63. Ascendis Pharma A/S has a 1 year low of $85.29 and a 1 year high of $161.00. The stock has a fifty day simple moving average of $135.16 and a 200 day simple moving average of $139.03.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.